IND-02(IND-02) - 药物靶点：APOBEC3G x HIV envelope protein gp120_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

APOBEC3G x HIV envelope protein gp120

作用机制

APOBEC3G modulators(ApoB editing catalytic polypeptide 3G modulators)、HIV包膜蛋白gp120调节剂

治疗领域-

在研适应症-

非在研适应症-

原研机构

Indus Biotech Pvt Ltd.

在研机构

Indus Biotech Pvt Ltd.

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 IND-02 相关的临床试验

CTRI/2020/11/029328 / Completed临床2期

A prospective, interventional, randomized, double-blind, placebo-controlled study to evaluate the safety and effectiveness of IND02 capsules (Cinamuneâ?¢) in SARS-CoV2 positive patients with mild to moderate COVID-19, managed as per the Government of India COVID-19 management guidelines, at COVID-19 management centres offering integrated Ayurvedic care.

开始日期2020-12-11

申办/合作机构

Indus Biotech Pvt Ltd.

CTRI/2020/10/028547 / Completed临床2/3期

Evaluation of intranasal application of IND02 for the prophylaxis against SARS-COV-2 infections in moderate to high risk population: A double blind placebo-controlled clinical study (IND02)

开始日期2020-10-29

申办/合作机构

Indus Biotech Pvt Ltd.

ACTRN12618000030279 / CompletedN/A

Pilot experimental study for safety and efficacy of IND02 (standardized hydroalcoholic extract of Cinnamonum zeylanicum bark extract) in reducing symptoms of Seasonal Allergic Rhinitis.

开始日期2018-01-20

申办/合作机构-

100 项与 IND-02 相关的临床结果

登录后查看更多信息

100 项与 IND-02 相关的转化医学

登录后查看更多信息

100 项与 IND-02 相关的专利（医药）

登录后查看更多信息

10

项与 IND-02 相关的文献（医药）

2019-12-01·Complementary Therapies in Medicine4区 · 医学

A randomized, double-blind placebo-controlled study of intranasal standardized cinnamon bark extract for seasonal allergic rhinitis

4区 · 医学

Article

作者: Dighe, Satish ; Deshpande, Pallavi ; Thakurdesai, Prasad ; Steels, Eleanor ; Collet, Trudi ; Steels, Elizabeth

OBJECTIVESThe aim of the study was to assess the safety and efficacy of a nasal spray containing a polyphenol-rich standardized extract of cinnamon bark (Cinnamomum zeylanicum) (IND02) for the treatment of seasonal allergic rhinitis (SAR).METHODSThis study was a randomized, double-blind, placebo-controlled study conducted in otherwise healthy men and women, aged between 18 and 75 years old, who were experiencing acute SAR symptoms. Participants were randomized in a 1:1 ratio to a nasal spray containing either IND02 (100 μg/100 μL) or matching placebo in each nostril, twice a day, for seven days.RESULTSThe outcome measures were the rhinoconjunctivitis quality of life questionnaire (RQLQ), the total daily symptom score comprising of day-time nasal, day-time eye, and night-time nasal symptom scores, the Work Productivity and Activities Impairment (WPAI:SHP), the Pittsburgh Sleep Quality Index (PSQI), the Perceived Stress Scale (PSS) and laboratory clinical parameters.RESULTSThe IND02 group showed a statistically and clinically significant reduction in total RQLQ and the sub-domains; activity limitation, sleep problems, nose symptoms, eye symptoms, non-nose/eye symptoms, practical problems and emotional function. There was a significant reduction in the total daily symptom score and sub-domains of total day-time nasal, total day-time eye and total night-time nasal symptoms scores, and total work impairment and regular activity impairment in the IND02 group compared with the placebo group after treatment. The laboratory clinical parameters remained within healthy normal reference range.CONCLUSIONThe use of a nasal spray of a standardized extract of cinnamon bark (IND02) over seven days reduced symptom severity and improved quality of life, work productivity and regular daily activities in participants experiencing SAR.

2017-09-01·Hepatology International2区 · 医学

A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry

2区 · 医学

Article

作者: Bhaskaran, Sunil ; Moog, Christiane ; Prakash, Ekambaranellore ; Lambotin, Melanie ; Heydmann, Laura ; Fauvelle, Catherine ; Vishwaraman, Mohan ; Baumert, Thomas F

BACKGROUND AND AIMSChronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. Although direct-acting antivirals can cure the large majority of treated patients, important limitations remain, including treatment failure and high costs precluding access to therapy in resource-limited settings. We report herein the anti-HCV effects of IND02, a procyanidin type A molecule, isolated and characterized from cinnamon.METHODS AND RESULTSUsing cellculture-derived HCV (HCVcc), HCV pseudoparticles (HCVpp), and subgenomic replicons, we demonstrated that IND02 markedly and dose-dependently inhibited HCV cell entry. Kinetic assays demonstrated that IND02 inhibits HCV entry most likely at a postbinding step. Experiments performed using primary human hepatocytes confirmed inhibition of HCV entry by IND02, demonstrating the functional impact in the most physiological cell-based system for studying HCV-host interactions.CONCLUSIONSThe natural compound IND02 exhibits potent HCV cell entry inhibition and provides a novel perspective for development of a low-cost antiviral for treatment of HCV infection.

2015-02-01·Bioorganic & Medicinal Chemistry3区 · 医学

IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells

3区 · 医学

Article

作者: Tiwari, Amit K ; Karthikeyan, Chandrabose ; Lee, Crystal ; Abbott, Kodye L ; Narayanan, Narayanan K ; Trivedi, Piyush ; Manne, Upender ; Suswam, Esther A ; Moore, Joshua ; Mittal, Roopali ; Pondugula, Satyanarayana R

Naturally occurring condensed quinolines have anticancer properties. In efforts to find active analogues, we designed and synthesized eight polycyclic heterocycles with a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline framework (IND series). The compounds were evaluated for activity against colon (HCT-116 and S1-MI-80), prostate (PC3 and DU-145), breast (MCF-7 and MDAMB-231), ovarian (ov2008 and A2780), and hepatocellular (HepG2) cancer cells and against non-cancerous Madin Darby canine kidney (MDCK), mouse embryonic fibroblast (NIH/3T3), and human embryonic kidney cells (HEK293). IND-2, a 4-chloro-2-methyl pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline, exhibited more than ten-fold selectivity and potent cytotoxic activity against colon cancer cells relative to the other cancer and non-cancer cells. With five additional colon cancer cell lines (HT-29, HCT-15, LS-180, LS-174, and LoVo), IND-2 had similar cytotoxicity and selectivity, and sub-micromolar concentrations caused changes in the morphology of HCT-116 and HCT-15 cells. IND-2 did not activate the transactivating function of the pregnane X receptor (PXR), indicating that it does not induce PXR-regulated ABCB1 or ABCG2 transporters. Indeed, IND-2 was not a substrate of ABCB1 or ABCG2, and it induced cytotoxicity in HEK293 cells overexpressing ABCB1 or ABCG2 to the same extent as in normal HEK293 cells. IND-2 was cytotoxic to resistant colon carcinoma S1-MI-80 cells, approximately three- and five-fold more than SN-38 and topotecan, respectively. In HCT-116 colon cancer cells, IND-2 produced concentration-dependent changes in mitochondrial membrane potential, leading to apoptosis, and sub-micromolar concentrations caused chromosomal DNA fragmentation. These findings suggest that, by increasing apoptosis, IND-2 has potential therapeutic efficacy for colorectal cancer.

100 项与 IND-02 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2023	N/A	前列腺癌	-	IND-2	憲鹹憲膚糧遞廠顧窪餘(選選襯繭選簾淵膚蓋襯) = The levels of reactive oxygen species (ROS) increased significantly after IND-2 was added to PC cells 膚糧齋衊選窪繭鑰網夢 (衊糧艱醖遞蓋夢簾窪窪 ) 更多	-	2023-04-04